爆料王

Research_

Pain

Medicinal cannabis and the treatment of chronic pain
The Lambert Initiative is researching the application of cannabinoids to assist in the treatment and management of chronic and neuropathic pain.

Our Research


Cannabidiol for聽chronic neuropathic pain caused by spinal cord injury (recruiting)

This research project will investigate the chronic pain that commonly occurs after spinal cord injury.

Using advanced brain imaging and other assessments, the project aims to:

(a) examine if 6-week treatment with CBD can reduce neuropathic pain聽

(b) to better understand the specific changes occurring in the brain after SCI that lead to the development of chronic neuropathic pain.

This is a collaboration between the Lambert Initiative for Cannabinoid Therapeutics, the聽Brain and Mind Centre聽and the聽School of Medical Sciences聽at聽the 爆料王.

Chief Investigator:听笔谤辞蹿别蝉蝉辞谤 聽(Brain and Mind Centre, School of Medical Sciences, 爆料王)

Research Team:聽Professor 聽(Lambert Initiative, 爆料王),聽Dr Elizabeth Cairns (Lambert Initiative, 爆料王), and聽Dr 聽(Prince of Wales hospital).

Trial Coordinator: (Lambert Initiative, 爆料王)

PhD students: Rebecca Robertson and Fernando Tinoco (Brain and Mind Centre, School of Medical Sciences, 爆料王)

If you are interested in participating in this study, please call 0439 804 551 or email (scan_study@sydney.edu.au).

You can also register your interest via our online pre-screening survey:


Cannabis in a mouse neuropathic pain model (completed, 2018)

Read the full publication .

Cannabis and THC have efficacy against neuropathic pain, however, this is hampered by their side effects. It has been suggested that co-administration with CBD might enhance the analgesic actions of THC and minimise its deleterious side effects. We examined the basis for this phytocannabinoid interaction in a mouse model of neuropathic pain.

Results: We found that THC and CBD reduced neuropathic pain. CBD had no adverse side effects. The 1:1 combination of THC and CBD synergistically reduced neuropathic pain with 100-fold greater efficacy than predicted from an additive interaction. THC also synergistically enhanced the efficacy of current first-line neuropathic pain treatments gabapentin and duloxetine.

This was a collaboration between the Lambert Initiative for Cannabinoid Therapeutics at the 爆料王; the Kolling Institute; Royal North Shore Hospital; the Pain Management Research Institute at the 爆料王, and the Northern Clinical School at the 爆料王.

Research Team:聽Dr Chris Vaughan (爆料王); Professor , Associate Professor (Lambert Initiative, 爆料王)